Provided by Tiger Trade Technology Pte. Ltd.

Harmony Biosciences Holdings, Inc.

27.06
-0.5400-1.96%
Volume:29.03K
Turnover:784.80K
Market Cap:1.56B
PE:9.99
High:27.36
Open:27.36
Low:26.77
Close:27.60
52wk High:40.87
52wk Low:25.52
Shares:57.60M
Float Shares:44.56M
Volume Ratio:0.81
T/O Rate:0.07%
Dividend:- -
Dividend Rate:- -
EPS(TTM):2.71
EPS(LYR):2.71
ROE:20.75%
ROA:11.48%
PB:1.79
PE(LYR):9.99

Loading ...

Harmony Biosciences CFO Sandip Kapadia Reports Disposal of Common Shares

Reuters
·
Dec 10, 2025

Harmony Biosciences Reports Promising Phase 3 Data for EPX-100 in Dravet Syndrome

Reuters
·
Dec 08, 2025

Harmony Biosciences (HRMY) Is Up 7.6% After GR Pitolisant Bioequivalence Win and Patent Runway Push

Simply Wall St.
·
Dec 05, 2025

Harmony Biosciences Unveils New Phase 3 ARGUS Trial Data on EPX-100 for Dravet Syndrome

Reuters
·
Dec 02, 2025

Mizuho Raises Price Target on Harmony Biosciences Holdings to $46 From $39, Keeps Outperform Rating

MT Newswires Live
·
Dec 01, 2025

Harmony Biosciences : Mizuho Raises Target Price to $46 From $39

THOMSON REUTERS
·
Dec 01, 2025

Harmony Biosciences Holdings (HRMY) Is Up 6.8% After Positive Pitolisant Study Results Are Patent Hopes Justified?

Simply Wall St.
·
Nov 28, 2025

Harmony Biosciences CFO Sandip Kapadia Reports Sale of Common Shares

Reuters
·
Nov 26, 2025

Positive Outlook on Harmony Biosciences Holdings: Promising Pipeline Developments and Revenue Growth Potential

TIPRANKS
·
Nov 25, 2025

BUZZ- Harmony Biosciences jumps as co announces positive results from sleep disorder drug study

Reuters
·
Nov 24, 2025

Harmony Biosciences Price Target Maintained With a $42.00/Share by Needham

Dow Jones
·
Nov 24, 2025

Promising Developments and Upcoming Catalysts Drive Buy Rating for Harmony Biosciences

TIPRANKS
·
Nov 24, 2025

Harmony Biosciences to Submit NDA for Narcolepsy Treatment Following Trial Results

MT Newswires Live
·
Nov 24, 2025

Harmony Biosciences Shares Rise 2% Premarket After Co Announces Positive Results From Sleep Disorder Drug Study

THOMSON REUTERS
·
Nov 24, 2025

Harmony Biosciences: New Drug Application to Be Submitted in Early 2026; Target Pdufa in Q1 2027

THOMSON REUTERS
·
Nov 24, 2025

Harmony Biosciences - No New Safety Issues Reported for Pitolisant Gr

THOMSON REUTERS
·
Nov 24, 2025

Harmony Biosciences: Utility Patent Applications Filed With Potential Exclusivity to 2044

THOMSON REUTERS
·
Nov 24, 2025

Harmony Biosciences Announces Positive Results From the Pivotal Bioequivalence Study for Pitolisant Gastro-Resistant Formulation

THOMSON REUTERS
·
Nov 24, 2025

Harmony Biosciences Reports Positive Bioequivalence Results for Pitolisant Gastro-Resistant Formulation

Reuters
·
Nov 24, 2025

BRIEF-Harmony Biosciences Announces Initiation Of First-In-Human Study With Potential Best-In-Class Orexin 2 Receptor Agonist (Bp1.15205) For Central Disorders Of Hypersomnolence

Reuters
·
Nov 19, 2025